Pharmacologic agents for the treatment of obesity

Clinics in Geriatric Medicine

Volumn 21, Issue 4, 2005, Pages 735-746

  Mathys, Monica ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMFEPRAMONE; AMPHETAMINE DERIVATIVE; ANTIHYPERTENSIVE AGENT; BENZPHETAMINE; CARBAMAZEPINE; CIMETIDINE; CYCLOSPORIN; ERYTHROMYCIN; FENTANYL; KETOCONAZOLE; METHAMPHETAMINE; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; PETHIDINE; PHENDIMETRAZINE; PHENTERMINE; PHENYTOIN; PSEUDOEPHEDRINE; RIFAMPICIN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; SUMATRIPTAN; TETRAHYDROLIPSTATIN; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN;

APPETITE; BEHAVIOR MODIFICATION; BODY MASS; CALORIC INTAKE; CALORIC RESTRICTION; CLINICAL TRIAL; CONSTIPATION; DEFECATION DISORDER; DIABETES MELLITUS; DIZZINESS; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERANCE; DYSPHORIA; ELDERLY CARE; EUPHORIA; EXERCISE; FECES INCONTINENCE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; LONG TERM CARE; MAINTENANCE THERAPY; METABOLIC PARAMETERS; METABOLIC RATE; NERVOUSNESS; NONHUMAN; OBESITY; PULMONARY HYPERTENSION; REVIEW; RHINITIS; SEROTONIN SYNDROME; SHORT COURSE THERAPY; SIDE EFFECT; STIMULATION; TREATMENT OUTCOME; VALVULAR HEART DISEASE; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION; XEROSTOMIA;

AGED; AMPHETAMINES; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CYCLOBUTANES; HUMANS; LACTONES; OBESITY;

EID: 25144477774     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2005.06.004     Document Type: Review

References (34)

1. CDC, National Center for Health Statistics, National Health and Nutrition Examination Survey. Health, United States (Table 70); 2002
2. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults Arch Intern Med 158 17 1998 1855 1867
3. M.L. Mathys, and M.L. Finnin Treatment of obesity in the elderly patient Clinical Geriatrics 10 7 2002 44 50
4. R.S. Stafford, and D.C. Radley National trends in antiobesity medication use Arch Intern Med 163 2003 1046 1050
5. Phentermine G.K. McEvoy AHFS drug information (online) 2004 American Society of Health-System Pharmacists Bethesda (MD)
6. Sibutramine G.K. McEvoy AHFS drug information (online) 2004 American Society of Health-System Pharmacists Bethesda (MD)
7. C.A. Luque, and J.A. Rey Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity Ann Pharmacother 33 1999 968 978
8. Sibutramine C.F. Lacy L.L. Armstrong M.P. Goldman Lexi-Comp's drug information handbook 2003 Lexi-Comp Hudson (OH)
9. F.G. McMahon, K. Fujioka, and N.S. Bramah Efficacy and safety of sibutramine in obese white and African American patients with hypertension Arch Intern Med 160 2000 2185 2191
10. W.P. James, A. Astrup, and N. Finer Effect of sibutramine on weight maintenance after weight loss: a randomized trial Lancet 356 2000 2119 2125
11. Sibutramine Clinical Study 1047 Team Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity J Fam Pract 50 6 2001 505 512
12. T.A. Wadden, R.I. Berkowitz, and D.B. Sarwer Benefits of lifestyle modification in the pharmacologic treatment of obesity Arch Intern Med 161 2001 218 227
13. C.A. Dujovne, J.H. Zavoral, and E. Rowe Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia Am Heart J 142 2001 489 497
14. Orlistat G.K. McEvoy AHFS drug information (online) 2004 American Society of Health-System Pharmacists Bethesda (MD)
15. J. Zhi, R. Moore, and L. Kanitra Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects J Clin Pharm 42 9 2002 1011 1019
16. R.S. MacWalter, W.F. Hazel, and K.M. Armstrong Orlistat enhances warfarin effect Ann Pharmacother 37 2003 510 512
17. E. Colman, and M. Fossler Reduction in blood cyclosporine concentrations by orlistat N Engl J Med 342 2000 1141 1142
18. J.S. Torgerson, J. Hauptman, and M.N. Boldrin Xenical in the prevention of diabetes in obese subjects (XENDOS) study Diabetes Care 27 2004 155 161
19. European Multicentre Orlistat Study Group Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients Lancet 352 1998 167 172
20. M.H. Davison, J. Hauptman, and M. DiGirolamo Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial JAMA 281 1999 235 242
21. J. Hauptman, C. Lucas, and M.N. Boldrin Orlistat in the long-term treatment of obesity in primary care settings Arch Fam Med 9 2000 160 167
22. I.G. Smith and the Sibutramine Clinical Study 1047 Team Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity J Fam Pract 50 6 2001 505 512
23. L. Sjostrom, A. Rissanen, and T. Anderson Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients Lancet 352 1998 167 172
24. S.B. Heymsfield, K.R. Segal, J. Hauptman, C. Lucas, M. Boldrin, and A. Rissanen Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults Arch Intern Med 160 2000 1321 1326
25. P.A. Hollander, S.C. Elbein, and I.B. Hirsch Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study Diabetes Care 21 8 1998 1288 1294
26. D.E. Kelly, G.A. Bray, and F.X. Pi-Sunyer Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes Diabetes Care 25 2002 1033 1041
27. J.M. Miles, L. Leiter, and P. Hollander Effect of orlistat on overweight and obese patients with type 2 diabetes treated with metformin Diabetes Care 25 2002 1123 1128
28. D.J. Cada, D.E. Baker, and T. Levien Orlistat Hosp Pharm 34 1999 1195 1213
29. K.R. Segal, C. Lucas, and M. Boldrin Weight loss efficacy of orlistat in obese elderly adults J Obes Research 7 Suppl 1 1999 26
30. I.D. Hind, J.E. Mangham, and S.P. Ghani Sibutramine pharmacokinetics in young and elderly healthy subjects Eur J Clin Pharmacol 54 11 1999 847 849
31. B.P. Hazenberg Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients Cardiology 94 2000 152 158
32. A. Gockel, H. Karakose, and E.M. Ertorer Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control Diabetes Care 24 2001 1957 1960
33. F. Lindgarde and the Orlistat Swedish Multimorbidity Study Group The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish multimorbidity study J Intern Med 248 2000 245 254
34. C.P. Lucas, M.N. Boldrin, and G.M. Reaven Effect of orlistat added to diet (30% of calories from fat) on plasma, lipids, glucose, and insulin in obese patients with hypercholesterolemia Am J Cardiol 91 2003 961 964